Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas/Cardiome Anticipate Oct. 19 Vernakalant User Fee Date

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma and Cardiome Pharma anticipate an Oct. 19, 2007, user fee date for vernakalant (RSD1235), an intravenous formulation for acute conversion of atrial fibrillation, based upon a 10-month standard FDA review. Astellas resubmitted the NDA for vernakalant Dec 19

Related Content

Sanofi Dronedarone Re-Filing Anticipated In 2008 After FDA “Non Approvable” Letter
Astellas Will Give Cardiome Accelerated Milestone Payment For Atrial Fibrillation Drug
FDA Refuses To File Cardiome/Astellas RSD1235 NDA





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts